



**To:** Members of the Governing Board  
**From:** Maria Bonneville, Vice Chair ICOC and Chair of the Access and Affordability Working Group  
**Re:** **Agenda Item # 7** - Appointment of a Member to the Accessibility & Affordability Working Group  
**Date:** June 27, 2024

---

As you know, Proposition 14 created the Treatments and Cures Accessibility and Affordability Working Group (AAWG) to recommend policies and programs to the Board to enhance access to, and the affordability of, treatments and cures arising from CIRM-funded research for California patients. The AAWG is composed of 17 members: seven members of the Board, including the Chair and Vice Chair, and 10 outside experts. Pursuant to Health & Safety Code section 125290.75, the Chair and Vice Chair of the Board are required to nominate members of the AAWG for approval by the Board.

I now wish to nominate Christina Hartman who fills the seat for a representative from patient advocacy organizations with experience in coverage, qualifications, and reimbursement of innovative therapies.

A copy of Christina Hartman's bio is attached.



## **Christina Hartman, MPH**

Christina serves as the Senior Director for Government Affairs at Orchard Therapeutics. She lives right outside Washington, DC in Bethesda, Maryland with her husband, Matt, and daughters Sophie (12) and Charlotte (7). Before joining Orchard, she led government affairs for bluebird bio, another rare disease gene therapy company. She also serves on the board of the US-based rare disease non-profit Global Genes. Christina is an active supporter of research for and education about Charlotte's (her daughter's), ultra-rare neurodevelopmental disorder, NAA10.

Before moving to the corporate side, Christina served as the Alliance for Regenerative Medicine (ARM)'s first-ever head of US Government Relations, where she leveraged the network she assembled over the past 25 years on the ground in Washington, DC to advance the priorities of the regenerative medicine sector. With a deep background in policy, government relations, alliance building and issue advocacy, she is committed to shaping an environment in Washington conducive to the discovery, development approval and accessibility of durable, potentially curative cell and gene therapies.

Before arriving at ARM, Christina built and led the Washington office of The Assistance Fund (TAF), where she advocated for patients to have access to all required clinical care, diagnostic testing, and treatment at an out-of-pocket cost within reach, regardless of socioeconomic status. Prior to that, Christina led policy and advocacy efforts to advance treatment and diagnostic opportunities for rare disease patients at the EveryLife Foundation, launching them for the first time in Washington, DC following their move from Novato, CA. At the Pew Charitable Trusts, she worked with a broad range of partners to advance legislative goals to incentivize the development of new antibiotic drugs. Early in her career, Christina served as an analyst at the US Department of Health and Human Services, including with the Biomedical Advanced Research and Development Authority (BARDA).

Christina has a Master of Public Health (MPH) with a concentration in epidemiology from the George Washington University School of Public Health. She is motivated every day to advance the priorities of the regenerative medicine sector as a direct result of her experience raising a child with an ultra-rare neurodevelopmental disorder.